PSNL · Personalis, Inc.
$15.95
+0.07 (+0.41%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$1.70B
Shares
106.80M
Volume · Oct 20
1.28M
Avg daily vol (3M)
3.12M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.88
Open$15.83
Day$15.75–16.02
52W close$5.04–18.38
Avg vol 30d2.3M
Short int8.4M · 7.9% float · 4.3d
Short vol44%
Last earningsAug 4, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 2 wks
filed Aug 4, 2026
call held May 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$69.67M
Trailing 12 months
Net income (TTM)
−$107.18M
Trailing 12 months
Revenue growth YoY
+30.0%
Year over year
Operating margin
-164.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+19.1%
Year over year · more shares
Price change (1Y)
+73.9%
Trailing year
Short interest
7.9%
Latest settlement · 4.3 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+45%
above
Price vs 50-day avg
−1%
below
RSI (14)
47
neutral
MACD trend
Negative
52-week position
81%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
+189%
trailing
YTD return
+100%
this year
Relative strength
+181%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $11 — 50d above 200d
Institutional flow
Distributing
8 of 158 funds reported for Sep 30 · net -49.0K sh shares · +4 new
Insider flow
Distributing
Net -$266.9K over 90 days · 100% sells
Short interest
Rising
7.89% of float · ▲ +2.0% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
158 holders — near 3-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
−18%
Y/Y
EPS growth
+34%
Y/Y
Free cash flow
$-79.5M
Balance sheet
$68.5M
net cash
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
2.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Total company revenue
· full year 2026
Maintained
$78M – $80M
Feb 26, 2026
$78M – $80M
changed to
May 7, 2026
$78M – $80M
prior FY $69.65M
midpoint +13.4% Y/Y
Clinical revenue
· full year 2026
Maintained
$10M – $11M
Feb 26, 2026
$10M – $11M
changed to
May 7, 2026
$10M – $11M
Revenue from pharma testing services and all other customers
· full year 2026
Maintained
$55M – $56M
Feb 26, 2026
$55M – $56M
changed to
May 7, 2026
$55M – $56M
Revenue from population sequencing and enterprise sales
· full year 2026
Maintained
$13M
Feb 26, 2026
$13M
changed to
May 7, 2026
$13M
Cash usage
· full year 2026
Maintained
$100M
Feb 26, 2026
$100M
changed to
May 7, 2026
$100M
Gross margin
· full year 2026
Maintained
15% – 20%
Feb 26, 2026
15% – 20%
changed to
May 7, 2026
15% – 20%
Prior guidance
period ended
· from the Earnings Call filed Nov 4, 2025
Total company revenue
· full year of 2025
$68M – $73M
Revenue from pharma tests and services and all other customers
· full year of 2025
$50M – $54M
Population sequencing plus enterprise customers revenue
· full year of 2025
$16.5M – $17M
Revenue from clinical tests reimbursed
· full year of 2025
$1.5M – $2M
Gross margin
· full year of 2025
22% – 24%
Cash usage
· full year of 2025
$75M
Guided vs delivered
· last 8 settled
Total company revenue
full year of 2025
guided $68M – $73M
$69.65M
In line
Total company revenue
fourth quarter of 2025
guided $15.7M – $20.7M
$17.35M
In line
Total company revenue
third quarter of 2025
guided $12M – $14M
$14.5M
Beat +11.5%
Total company revenue
third quarter of 2024
guided $21M – $22M
$25.71M
Beat +19.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+45%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
81%
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $16 › 200d $11 — 50d above 200d
Institutional flow
Distributing
8 of 158 funds reported for Sep 30 · net -49.0K sh shares · +4 new
Insider flow
Distributing
Net -$266.9K over 90 days · 100% sells
Short interest
Rising
7.89% of float · ▲ +2.0% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
158 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $16 · 81%
Range high $18
vs 200-day avg +45%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and short-term investments | 212.7M | end of Q2 2026 | — |
| Clinical revenue | 2.6M | Q2 2026 | — |
| Clinical test revenue | 2.6M | three months ended June 30, 2026 | — |
| Clinical test volume | 10,384 | Q2 2026 | — |
| Merck & Co., Inc. | 37% | the three months ended June 30, 2026 filing | — |
| ModernaTX, Inc. | 12% | the three months ended June 30, 2026 filing | — |
| Revenue from pharma testing services and all other customers | 16.8M | Q2 2026 | — |
| Revenue from population sequencing (the VA MVP) | 3M | Q2 2026 | — |
| VA MVP | 13% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PSNL
this stock
Personalis, Inc.
|
$1.70B | +99.5% | -17.7% | — | 7.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$251.20B | +17.2% | +14.5% | 36.6 | 1.5% |
|
DHR
Danaher Corp /De/
|
$157.77B | -2.0% | +8.5% | 39.8 | 1.3% |
|
NTRA
Natera, Inc.
|
$57.57B | +74.4% | -2.8% | — | 4.4% |
|
A
Agilent Technologies, Inc.
|
$48.56B | +24.9% | +6.4% | 33.9 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PSNL | +0.5% | -2.2% | +188.7% | -2.5% | +99.5% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +2.0% | -1.3% | +181.0% | -3.0% | +87.1% |